Scholar Rock is a biotechnology company focused on discovering and developing niche modulators, a novel class of biologic therapies that selectively modulate the activation of growth factors in the disease microenvironment. The Company's initial proprietary and partnered drug discovery programs target specific growth factors, including members of the TGF-beta superfamily, which are present in the microenvironments of significant diseases such as fibrosis, diseases of the musculoskeletal systems and autoimmune diseases. Scholar Rock was founded based on discoveries made by its scientific founders, Professors Tim Springer, PhD, and Leonard Zon, MD, of Boston Children's Hospital and Harvard Medical School, related to the molecular mechanisms of growth factor activation.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
09/15/14	$20,000,000	Series A	ARCH Venture Partners EcoR1 Capital Kraft Group Polaris Partners Timothy Springer	undisclosed
01/04/16	$36,000,000	Series B	ARCH Venture Partners Cormorant Asset Management EcoR1 Capital Fidelity Investments Kraft Group Polaris Partners Timothy Springer	undisclosed
01/03/18	$47,000,000	Series C	ARCH Venture Partners Cormorant Asset Management EcoR1 Capital Fidelity Management & Research Company Invus Kraft Group Polaris Partners Redmile Group Timothy Springer	undisclosed